Allergen Research Corporation announced additions to the company's board of directors, Mark McDade, joining as chairman; and Mark Iwicki, joining as a member of the board. McDade is a global pharmaceutical operations executive with nearly 30 years of experience, and Iwicki has managed all stages of drug development and commercialization in multiple therapeutic areas during his 25-year career. McDade is executive vice president and chief operating officer of UCB.

At UCB, McDade leads worldwide geographic operations, established brands, technical operations and business development. Previously, McDade served as CEO and as a director of PDL Biopharma. He was also CEO of Signature Bioscience; founder, chief operating officer, president and a director of Corixa Corporation; and chief operating officer of Boehringer Mannheim Therapeutics.

He serves on the boards of directors of Five Prime Therapeutics and Dermira. Iwicki is executive chairman of the board of directors of Kala Pharmaceuticals and sits on the boards of Nimbus Therapeutics and Taris Biomedical. He was president and CEO of Civitas Therapeutics until late 2014.